Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care
Sandoz has launched the Sandoz mobile health initiative in Portugal through its “Sandoz em Marcha” project, sending a mobile health unit to 16 localities over two months to deliver free screenings and health educ...
Navigating the Challenges of Patient-Centered AI Systems in Postpartum Depression Care
Patient-centered AI systems can improve care, but moving them from labs to clinics without causing harm remains a critical challenge. A recent qualitative study explored this question by capturing the perspectives of patients, healthcare professionals, and developers, using a postpartum depressio...
JNJ-4804 IBD Therapy Proves Effective for Refractory Inflammatory Bowel Disease
JNJ-4804 IBD therapy offers new hope for patients with hard-to-treat inflammatory bowel disease. This co-antibody treatment combines two proven mechanisms in a single injection. It targets IL-23 and TNF-α pathways at once. Recent Phase 2b results support its move into larger trials. Johnson &a...